Cipla partners with Qilu to license Keytruda biosimilar for U.S.
India’s Cipla said its U.S. unit entered an exclusive partnership with China’s Qilu Pharmaceutical to license a biosimilar version of Merck’s Keytruda for the U.S. market.
India's Cipla NSE:CIPLA said on Thursday its U.S. unit entered an exclusive partnership with China's Qilu Pharmaceutical to license a biosimilar version of Merck's NYSE:MRK cancer drug Keytruda for the U.S. market.Here are more details